Osteoporosis in primary biliary cholangitis

Table 2 Summary of results in comparative randomized controlled trials of different agents for treatment of osteoporosis in primary biliary cholangitis

Agent	Treatment	No. of patients (n)	BMD changes at 1 yr (%)	BMD changes at 2 yr (%)	Fractures (n)
Guañabens et al[39], 1997
Etidronate	400 mg/d (3 mo cycles)	13 (etidronate)	-0.1 (L), -0.4 (F)	+0.5 (L)2, -0.2 (F)	0 (V), 3 (P)
Sodium fluoride	50 mg/d sodium fluoride	10 (fluoride)	-1.7 (L), -0.6 (F)	-2.1 (L), -1.5 (F)	2 (V), 2 (P)
Guañabens et al[45], 2003
Alendronate	10 mg/d	13 (alendronate)		+5.8 (L)12, +3.9 (F)12	0 (V), 2 (P)
Etidronate	400 mg/d (3 mo cycles)	13 (etidronate)		+1.9 (L)1, +0.4 (F)1	0 (V), 1 (P)
Guañabens et al[2], 2005
Alendronate	10 mg/d	16 (alendronate)	+3.3 (L)2, +1.2 (F)2
Alendronate	70 mg/wk	10 (alendronate)	+1.2 (L), -0.3 (F)
Guañabens et al[46], 2013
Ibandronate	150 mg/mo	14 (ibandronate)	+3.8 (L), +1.0 (F)	+5.7 (L)2, +1.1 (F)	0 (V), 0 (P)
Alendronate	70 mg/wk	19 (alendronate)	+4.6 (L), +1.4 (F)	+4.5 (L)2, +2.5 (F)	1 (V), 0 (P)

¹Statistical significance (P < 0.05) between groups;

²Statistical difference (P < 0.05) from baseline. L: Lumbar; F: Femoral; V: Vertebral; P: Peripheral; BMD: Bone mineral density.